4SC 205

Drug Profile

4SC 205

Alternative Names: 4SC-205

Latest Information Update: 08 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nycomed
  • Developer 4SC
  • Class Antineoplastics; Small molecules
  • Mechanism of Action KIF11 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 08 Jun 2016 4SC 205 is available for licensing in countries, except China, Hong Kong, Taiwan and Macao, as of 31 May 2016. http://www.4sc.com
  • 31 May 2016 4SC 205 licensed to Link Health in China, Hong Kong, Taiwan and Macao
  • 31 May 2016 Link Health plans a clinical trial for Cancer in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top